Journal
ONCOGENE
Volume 20, Issue 20, Pages 2587-2599Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1204362
Keywords
SUMO-1; p53; transactivation; cellular localization
Funding
- NCI NIH HHS [CA75179] Funding Source: Medline
- NIDDK NIH HHS [R01 DK056283] Funding Source: Medline
- NIEHS NIH HHS [ES08353] Funding Source: Medline
Ask authors/readers for more resources
p53 tumor suppressor is a subject of several posttranslational modifications, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modification of p53 at lysine 386 by SUMO-1 was recently identified. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-deficient p53 mutant, K386R, No differences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no effect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 colocalized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-deficient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modification of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available